5/6/2009

Amylin Pharmaceuticals submitted exenatide, a once-weekly injectable version of Type 2 diabetes drug Byetta, for FDA approval. The application is backed by data from clinical trials that prove exenatide is more effective than tablet forms of diabetes drugs for controlling blood sugar.

Related Summaries